BLCO Bausch & Lomb Corp
Ophthalmic Goods · NYSE · SEC CIK 1860742 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.9%
TTM net income YoY63.6%
TTM EPS YoY62.8%
Revenue 3-yr CAGR10.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin7.1%
Net margin-2.0%
FCF margin4.7%
EBITDA margin14.5%
Returns
ROE-1.7%
ROA-0.8%
ROIC (approx.)2.8%
Asset turnover0.39x
Leverage & solvency
Liabilities / assets53.4%
Debt / equity0.78x
Current ratio1.56x
Interest coverage1.00x
Cash quality & payout
Operating cash flow / net income-4.99x
Accruals ratio-4.8%
Payout ratio—
Capex / revenue5.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.38B | $1.39B | $1.24B | $1.41B | $1.28B | $1.28B | $1.14B | $1.28B |
| R&D expense | $91.00M | $114.00M | $101.00M | $94.00M | $95.00M | $96.00M | $86.00M | $93.00M |
| SG&A expense | $556.00M | $588.00M | $544.00M | $564.00M | $528.00M | $579.00M | $563.00M | $532.00M |
| Operating income | $155.00M | $83.00M | $33.00M | $112.00M | $95.00M | -$11.00M | -$83.00M | $87.00M |
| Interest expense | $95.00M | $93.00M | $97.00M | $98.00M | $101.00M | $128.00M | $94.00M | $98.00M |
| Pretax income | $58.00M | -$11.00M | -$64.00M | $13.00M | -$3.00M | -$147.00M | -$180.00M | -$10.00M |
| Income tax | $23.00M | -$1.00M | $6.00M | $71.00M | $22.00M | -$89.00M | $31.00M | -$8.00M |
| Net income | $32.00M | -$14.00M | -$71.00M | -$58.00M | -$28.00M | -$62.00M | -$212.00M | -$3.00M |
| EBITDA | $257.00M | $185.00M | $134.00M | $211.00M | $204.00M | $96.00M | $23.00M | $193.00M |
| EPS (basic) | 0.09 | -0.04 | -0.20 | — | -0.08 | -0.18 | -0.60 | — |
| EPS (diluted) | 0.09 | -0.04 | -0.20 | — | -0.08 | -0.18 | -0.60 | — |
| Weighted avg. shares (diluted) | 361.50M | 357.10M | 355.20M | — | 354.20M | 353.70M | 352.80M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $513.00M | $367.00M | $268.00M | $383.00M | $332.00M | $272.00M | $215.00M | $316.00M |
| Receivables | $1.15B | $1.16B | $1.11B | $1.22B | $1.09B | $1.08B | $1.01B | $1.03B |
| Inventory | $1.01B | $999.00M | $977.00M | $976.00M | $1.00B | $1.05B | $1.03B | $1.04B |
| Current assets | $3.06B | $2.92B | $2.78B | $2.98B | $2.85B | $2.85B | $2.69B | $2.79B |
| PP&E, net | $1.81B | $1.80B | $1.79B | $1.76B | $1.71B | $1.68B | $1.58B | $1.49B |
| Goodwill | $4.71B | $4.72B | $4.74B | $4.76B | $4.66B | $4.67B | $4.57B | $4.52B |
| Intangibles | $3.13B | $3.17B | $3.23B | $3.28B | $3.33B | $3.36B | $3.43B | $3.49B |
| Total assets | $13.96B | $13.86B | $13.78B | $14.02B | $13.83B | $13.83B | $13.43B | $13.47B |
| Current liabilities | $1.96B | $1.89B | $1.82B | $1.92B | $1.90B | $1.84B | $1.73B | $1.74B |
| Short-term debt | $28.00M | $28.00M | $28.00M | $28.00M | $28.00M | $28.00M | $40.00M | $40.00M |
| Long-term debt | $4.99B | $5.05B | $5.01B | $5.02B | $4.92B | $4.93B | $4.79B | $4.74B |
| Total debt | $5.02B | $5.08B | $5.04B | $5.05B | $4.95B | $4.96B | $4.83B | $4.78B |
| Total liabilities | $7.45B | $7.42B | $7.33B | $7.50B | $7.33B | $7.32B | $7.00B | $6.92B |
| Shareholders' equity | $6.44B | $6.38B | $6.38B | $6.45B | $6.43B | $6.44B | $6.36B | $6.47B |
| Net debt | $4.50B | $4.71B | $4.77B | $4.67B | $4.62B | $4.69B | $4.61B | $4.47B |
| Shares outstanding | 357.39M | 357.06M | 356.40M | 354.21M | 354.09M | 353.80M | 353.36M | 352.40M |
| Cash flow statement | ||||||||
| Operating cash flow | $233.00M | $153.00M | $32.00M | $136.00M | $137.00M | $35.00M | -$25.00M | $22.00M |
| Capital expenditure | $55.00M | $71.00M | $100.00M | $76.00M | $74.00M | $89.00M | $110.00M | $92.00M |
| Free cash flow | $178.00M | $82.00M | -$68.00M | $60.00M | $63.00M | -$54.00M | -$135.00M | -$70.00M |
| Investing cash flow | -$73.00M | -$87.00M | -$130.00M | -$188.00M | -$61.00M | -$90.00M | -$116.00M | -$185.00M |
| Financing cash flow | -$22.00M | $34.00M | -$20.00M | $116.00M | -$12.00M | $90.00M | $31.00M | $146.00M |
| Depreciation & amortization | $102.00M | $102.00M | $101.00M | $99.00M | $109.00M | $107.00M | $106.00M | $106.00M |
| Stock-based compensation | $37.00M | $38.00M | $34.00M | $64.00M | $27.00M | $30.00M | $28.00M | $27.00M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.